Sadašnja situacija i buduće perspektive korona virusne bolesti 2019 - pregled
COVID-19 pandemija
Ključne reči:
SARS-CoV-2, COVID-19, korona virus, svet, pandemija
Sažetak
A novel infectious disease named coronavirus disease-2019 (COVID-19) first emerged in Wuhan, China, in December 2019 and rapidly spread worldwide. In March 2020 the World Health Organization declared a global pandemic which is the worst global public health crisis in over 100 years. On 14 June 2020, almost eight million confirmed cases of COVID-19 and more than 430,000 deaths globally were reported. Over 200 countries have been affected so far. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the absence of specific therapy and vaccine, effective infection control intervention, particularly self-hygiene and social distancing, is the only way to prevent the spread of SARS-CoV-2. The lessons learned from this pandemic will be useful for successful management of the second wave of COVID-19 which is expected in autumn or winter.
Reference
1. Zhong NS, Zheng BJ, Li YM, Poon LLM, Xie ZH, Chan KH et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China in February 2003. Lancet 2003;362:1353−8.
2. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci 2018;22:4956−61.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
4. World Health Organisation. Novel Coronavirus (2019-nCoV). Situation report - 11. Geneva, WHO, 31 January 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/(accessed June 14, 2020).
5. World Health Organization. Coronavis disease 2019 (COVID-19). Situation report - 51. Geneva: WHO, March 11, 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 14, 2020).
6. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676−9.
7. Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol 2014;88:11297−303.
8. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-2019). Geneva: WHO, 16−24 February 2020. Available at: http://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (accessed June 13, 2020).
9. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020;16:1686–97.
10. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020;105951. doi:10.1016/j.ijantimicag.2020.105951
11. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246−51.
12. BBC news. Coronavirus pandemic: tracking the global outbreak. Available at: https://www.bbc.com/news/world-51235105 (accessed June 14, 2020).
13. Worldometer. COVID-19 Coronavirus pandemic. Available at: https://www.worldometers.info/coronavirus/ (accessed June 14, 2020).
14. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention#H3174740477 (accessed June 13, 2020).
15. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVD-19) China CDC Weekly. 2020;2:113–22.
16. Wenham C, Smith J, Morgan R, Gender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet 2020;395:846−8.
17. Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
18. Mantovani A, Dalbeni A, Beatrice G. Coronavirus disease 2019 (COVID-19): we don't leave women alone. Int J Public Health 2020;65:235−6.
19. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401–2.
20. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514−23.
21. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020;20:124–7.
22. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;e201585. doi:10.1001/jama.2020.1585
23. McMichael TM, Clark S, Pogosjans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a long-term care facility - King County, Washington, February 27−March 9, 2020. MMWR Morb Mortal Wkly Rep 2020;69:339−42.
24. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020;jiaa077. doi:10.1093/infdis/jiaa077
25. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406−7.
26. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125−32.
27. Ren SY, Wang WB, Hao YG, Zhang HR, Wang ZC, Chen YL, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases 2020;8:1391−9.
28. Public Health Ontario. Synopsis. COVID-19 – What We Know So Far About…Routes of transmission. 28 April 2020. Available at: www.publichealthontario.ca › ncov › covid-wwks (accessed June 12, 2020).
29. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report - 73. Geneva: WHO, 2 April 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 12, 2020).
30. Public Health Ontario. Synopsis. COVID-19 – What We Know So Far About…The Period of Communicability. March, 30, 2020. Available at: www.publichealthontario.ca › ncov › covid-wwks (accessed June 12, 2020).
31. Wu, JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020;395:689–97.
32. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 [published online ahead of print, 2020 Apr 7]. Emerg Infect Dis 2020;26(7):10.3201/eid2607.200282. doi:10.3201/eid2607.200282
33. Moore KA, Lipsitch M, Barry JM, Osterholm MT. COVID-19: The CIDRAP viewpoint. Part 1. The future of the COVID-19 pandemic: Lessons learned from pandemic influenza. Report April 30th, 2020. University of Minnesota. Available at: https://www.cidrap.umn.edu/covid-19/covid-19-cidrap-viewpoint (Accessed June 14, 2020).
34. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708.
35. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med pii: S2213-2600(20)30079-5.
36. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. doi: 10.1111/all.14238
37. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;101623. doi:10.1016/j.tmaid.2020.101623
38. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91−5.
39. NCDHHS: COVID 19 response. People at high risk for severe illness. North Carolina Department of Health and Human Services. Available at: http: www.ncdhhs.gov (accessed June 12, 2020).
40. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu Guogang, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020;109:102434. doi:10.1016/j.jaut.2020.102434
41. Lai CC, Liu YH, Wang CY, Wang HY, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect 2020; doi:10.1016/j.jmii.2020.02.012
42. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425.
43. Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect 2020;35:100679. doi:10.1016/j.nmni.2020.100679
44. WHO Director-General's opening remarks at the media briefing on COVID-19 - 24 February 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020 (accessed June 13, 2020).
45. European Centre for Disease Prevention and Control. Case definition coronavirus disease 2019 (COVID-19). Available at: www.ecdc.europa.eu › covid-19-pandemic (accessed June 13, 2020).
46. WHO. Clinical management of COVID-19. Interim guidance. 27 May 2020. World Health Organization, 2020. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19 (accesed June 14, 2020).
47. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30:313–24.
48. Stajić M, Maksimović Ž. COVID-19 pneumonia: when negative PCR testing does not rule out the disease. Scr Med 2020;51(2). DOI:10.5937/scriptamed51-25960
49. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. doi: 10.1001/jama.2020.8259.
50. Lou B, Li T, Zheng S, Su Y, LiZ, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. Preprint posted 27 March 2020. doi:10.1101/2020.03.23.20041707
51. CDC. Coronavirus disease 2019 (COVID-19). Testing for COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html (accessed June 13, 2020).
52. WHO. "Immunity passports" in the context of COVID-19. 24 April 2020. World Health Organization, 2020. Available at: https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19 (Accessed June 14, 2020).
53. WHO. Updated WHO advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV. Geneva: WHO, 24 January 2020. Available at: https://www.who.int/ith/2020-24-01-outbreak-of-Pneumonia-caused-by-new-coronavirus/en/(accessed June 13, 2020).
54. Mayr V, Nußbaumer-Streit B, Gartlehner G. Quarantäne alleine oder in Kombination mit weiteren Public-Health-Maßnahmen zur Eindämmung der COVID-19 Pandemie: Ein Cochrane Rapid Review [Quarantine Alone or in Combination with Other Public Health Measures to Control COVID-19: A Rapid Review (Review)] [published online ahead of print, 2020 May 15]. Gesundheitswesen. 2020;10.1055/a-1164-6611. doi:10.1055/a-1164-6611
55. Abel T, McQueen D. The COVID-19 pandemic calls for spatial distancing and social closeness: not for social distancing! Int J Public Health 2020;65:231.
56. WHO. Advice on the use of masks in the context of the novel coronavirus (2019-nCoV) outbreak. April 6, 2020. Geneva: WHO. Available at: https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak (accessed June 13, 2020).
57. Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med 2020;S2213-2600(20)30134-X. doi:10.1016/S2213-2600(20)30134-X
58. Centers for Disease Control and Prevention. Public health recommendations for people in U.S. Communities exposed to a person with known or suspected COVID-19, other than health workers or other critical infrastructure workers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html (accessed June 13, 2020).
59. Centers for Disease Control and Prevention. Public health recommendations after travel-associated COVID-19 exposure. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html (accessed June 13, 2020).
60. Palmore T. Coronavirus disease 2019 (COVID-19): Infection control in health care and home settings In: McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-infection-control-in-health-care-and-home-settings?topicRef=126981&source=see_link (accessed June 13, 2020).
61. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. Published online 11 May 2020. doi:10.1001/jama.2020.7869
62. Euronews. Analysis: How close are we to COVID-19 herd immunity? Available at: https://www.euronews.com/2020/05/15/analysis-how-close-are-we-to-covid-19-herd-immunity (accessed June 13, 2020).
63. Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020;80(6):e32‐e33. doi:10.1016/j.jinf.2020.03.027
64. Mahase E. Covid-19: What do we know so far about a vaccine? BMJ. 2020;369:m1679. doi:10.1136/bmj.m1679
65. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health 2020;8(5):e639-e640.
66. World Health Organization. Coronavis disease 2019 (COVID-19). Situation report - 8. Geneva: WHO, 28 January 28 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 13, 2020).
67. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020;395(10224):e35-e36.
68. Centers for Disease Control and Prevention (CDC). Information for clinicians on investigational therapeutics for patients with COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (accessed June 14, 2020).
69. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). Available at: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html (accessed June 14, 2020).
70. NIH. COVID-19 Treatment Guidelines. What's New in the Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/whats-new/ (accessed June 13, 2020).
71. Khan Z, Karataş Y, Rahman H. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action [published online ahead of print, 2020 Apr 29]. Adv Ther 2020;1‐5. doi:10.1007/s12325-020-01351-9
72. Rubin R. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19. JAMA Published online April 30, 2020. doi:10.1001/jama.2020.7456
73. Begley S. Three potential futures for Covid-19: recurring small outbreaks, a monster wave, or a persistent crisis. Available at: https://www.statnews.com/2020/05/01/three-potential-futures-for-covid-19/ (accessed June 14, 2020).
74. Lee A. Wuhan novel coronavirus (COVID-19): why global control is challenging? Public Health 2020;179:A1–A2. doi:10.1016/j.puhe.2020.02.001
2. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci 2018;22:4956−61.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
4. World Health Organisation. Novel Coronavirus (2019-nCoV). Situation report - 11. Geneva, WHO, 31 January 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/(accessed June 14, 2020).
5. World Health Organization. Coronavis disease 2019 (COVID-19). Situation report - 51. Geneva: WHO, March 11, 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 14, 2020).
6. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676−9.
7. Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol 2014;88:11297−303.
8. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-2019). Geneva: WHO, 16−24 February 2020. Available at: http://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (accessed June 13, 2020).
9. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020;16:1686–97.
10. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020;105951. doi:10.1016/j.ijantimicag.2020.105951
11. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246−51.
12. BBC news. Coronavirus pandemic: tracking the global outbreak. Available at: https://www.bbc.com/news/world-51235105 (accessed June 14, 2020).
13. Worldometer. COVID-19 Coronavirus pandemic. Available at: https://www.worldometers.info/coronavirus/ (accessed June 14, 2020).
14. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention#H3174740477 (accessed June 13, 2020).
15. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVD-19) China CDC Weekly. 2020;2:113–22.
16. Wenham C, Smith J, Morgan R, Gender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet 2020;395:846−8.
17. Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
18. Mantovani A, Dalbeni A, Beatrice G. Coronavirus disease 2019 (COVID-19): we don't leave women alone. Int J Public Health 2020;65:235−6.
19. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401–2.
20. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514−23.
21. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020;20:124–7.
22. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;e201585. doi:10.1001/jama.2020.1585
23. McMichael TM, Clark S, Pogosjans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a long-term care facility - King County, Washington, February 27−March 9, 2020. MMWR Morb Mortal Wkly Rep 2020;69:339−42.
24. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020;jiaa077. doi:10.1093/infdis/jiaa077
25. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406−7.
26. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125−32.
27. Ren SY, Wang WB, Hao YG, Zhang HR, Wang ZC, Chen YL, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases 2020;8:1391−9.
28. Public Health Ontario. Synopsis. COVID-19 – What We Know So Far About…Routes of transmission. 28 April 2020. Available at: www.publichealthontario.ca › ncov › covid-wwks (accessed June 12, 2020).
29. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report - 73. Geneva: WHO, 2 April 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 12, 2020).
30. Public Health Ontario. Synopsis. COVID-19 – What We Know So Far About…The Period of Communicability. March, 30, 2020. Available at: www.publichealthontario.ca › ncov › covid-wwks (accessed June 12, 2020).
31. Wu, JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020;395:689–97.
32. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 [published online ahead of print, 2020 Apr 7]. Emerg Infect Dis 2020;26(7):10.3201/eid2607.200282. doi:10.3201/eid2607.200282
33. Moore KA, Lipsitch M, Barry JM, Osterholm MT. COVID-19: The CIDRAP viewpoint. Part 1. The future of the COVID-19 pandemic: Lessons learned from pandemic influenza. Report April 30th, 2020. University of Minnesota. Available at: https://www.cidrap.umn.edu/covid-19/covid-19-cidrap-viewpoint (Accessed June 14, 2020).
34. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708.
35. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med pii: S2213-2600(20)30079-5.
36. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. doi: 10.1111/all.14238
37. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;101623. doi:10.1016/j.tmaid.2020.101623
38. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91−5.
39. NCDHHS: COVID 19 response. People at high risk for severe illness. North Carolina Department of Health and Human Services. Available at: http: www.ncdhhs.gov (accessed June 12, 2020).
40. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu Guogang, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020;109:102434. doi:10.1016/j.jaut.2020.102434
41. Lai CC, Liu YH, Wang CY, Wang HY, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect 2020; doi:10.1016/j.jmii.2020.02.012
42. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425.
43. Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect 2020;35:100679. doi:10.1016/j.nmni.2020.100679
44. WHO Director-General's opening remarks at the media briefing on COVID-19 - 24 February 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020 (accessed June 13, 2020).
45. European Centre for Disease Prevention and Control. Case definition coronavirus disease 2019 (COVID-19). Available at: www.ecdc.europa.eu › covid-19-pandemic (accessed June 13, 2020).
46. WHO. Clinical management of COVID-19. Interim guidance. 27 May 2020. World Health Organization, 2020. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19 (accesed June 14, 2020).
47. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30:313–24.
48. Stajić M, Maksimović Ž. COVID-19 pneumonia: when negative PCR testing does not rule out the disease. Scr Med 2020;51(2). DOI:10.5937/scriptamed51-25960
49. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. doi: 10.1001/jama.2020.8259.
50. Lou B, Li T, Zheng S, Su Y, LiZ, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. Preprint posted 27 March 2020. doi:10.1101/2020.03.23.20041707
51. CDC. Coronavirus disease 2019 (COVID-19). Testing for COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html (accessed June 13, 2020).
52. WHO. "Immunity passports" in the context of COVID-19. 24 April 2020. World Health Organization, 2020. Available at: https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19 (Accessed June 14, 2020).
53. WHO. Updated WHO advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV. Geneva: WHO, 24 January 2020. Available at: https://www.who.int/ith/2020-24-01-outbreak-of-Pneumonia-caused-by-new-coronavirus/en/(accessed June 13, 2020).
54. Mayr V, Nußbaumer-Streit B, Gartlehner G. Quarantäne alleine oder in Kombination mit weiteren Public-Health-Maßnahmen zur Eindämmung der COVID-19 Pandemie: Ein Cochrane Rapid Review [Quarantine Alone or in Combination with Other Public Health Measures to Control COVID-19: A Rapid Review (Review)] [published online ahead of print, 2020 May 15]. Gesundheitswesen. 2020;10.1055/a-1164-6611. doi:10.1055/a-1164-6611
55. Abel T, McQueen D. The COVID-19 pandemic calls for spatial distancing and social closeness: not for social distancing! Int J Public Health 2020;65:231.
56. WHO. Advice on the use of masks in the context of the novel coronavirus (2019-nCoV) outbreak. April 6, 2020. Geneva: WHO. Available at: https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak (accessed June 13, 2020).
57. Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med 2020;S2213-2600(20)30134-X. doi:10.1016/S2213-2600(20)30134-X
58. Centers for Disease Control and Prevention. Public health recommendations for people in U.S. Communities exposed to a person with known or suspected COVID-19, other than health workers or other critical infrastructure workers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html (accessed June 13, 2020).
59. Centers for Disease Control and Prevention. Public health recommendations after travel-associated COVID-19 exposure. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html (accessed June 13, 2020).
60. Palmore T. Coronavirus disease 2019 (COVID-19): Infection control in health care and home settings In: McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-infection-control-in-health-care-and-home-settings?topicRef=126981&source=see_link (accessed June 13, 2020).
61. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. Published online 11 May 2020. doi:10.1001/jama.2020.7869
62. Euronews. Analysis: How close are we to COVID-19 herd immunity? Available at: https://www.euronews.com/2020/05/15/analysis-how-close-are-we-to-covid-19-herd-immunity (accessed June 13, 2020).
63. Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020;80(6):e32‐e33. doi:10.1016/j.jinf.2020.03.027
64. Mahase E. Covid-19: What do we know so far about a vaccine? BMJ. 2020;369:m1679. doi:10.1136/bmj.m1679
65. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health 2020;8(5):e639-e640.
66. World Health Organization. Coronavis disease 2019 (COVID-19). Situation report - 8. Geneva: WHO, 28 January 28 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed June 13, 2020).
67. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020;395(10224):e35-e36.
68. Centers for Disease Control and Prevention (CDC). Information for clinicians on investigational therapeutics for patients with COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (accessed June 14, 2020).
69. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). Available at: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html (accessed June 14, 2020).
70. NIH. COVID-19 Treatment Guidelines. What's New in the Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/whats-new/ (accessed June 13, 2020).
71. Khan Z, Karataş Y, Rahman H. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action [published online ahead of print, 2020 Apr 29]. Adv Ther 2020;1‐5. doi:10.1007/s12325-020-01351-9
72. Rubin R. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19. JAMA Published online April 30, 2020. doi:10.1001/jama.2020.7456
73. Begley S. Three potential futures for Covid-19: recurring small outbreaks, a monster wave, or a persistent crisis. Available at: https://www.statnews.com/2020/05/01/three-potential-futures-for-covid-19/ (accessed June 14, 2020).
74. Lee A. Wuhan novel coronavirus (COVID-19): why global control is challenging? Public Health 2020;179:A1–A2. doi:10.1016/j.puhe.2020.02.001
Objavljeno
2020/04/04
Broj časopisa
Rubrika
Review article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).